[Form 4/A] BIOXYTRAN, INC Amended Insider Trading Activity

Rhea-AI Filing Summary

Bioxytran, Inc. insider David Platt, who serves as CEO, director, and a 10% owner, reported changes in his indirect holdings of preferred stock on a Form 4/A. On 10/24/2024, 14,085,410 preferred shares held through NDPD Pharma were returned to treasury and cancelled. On the same date, 11,433,448 preferred shares were issued as payment for the sale of NDPD to Bioxytran, leaving Platt with 20,038,903 preferred shares beneficially owned indirectly through NDPD Pharma. The filing consolidates NDPD Pharma’s Bioxytran holdings under Platt’s indirect ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

PLATT DAVID

(Last) (First) (Middle)

12 APPLETON CIRCLE

(Street)

NEWTON MA 02459

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOXYTRAN, INC [ BIXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
10/24/2024

4. If Amendment, Date of Original Filed (Month/Day/Year)
10/24/2024

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
preferred	10/24/2024		J(1)		14,085,410	D	$0.285	0	I	through NDPD Pharma(2)
preferred	10/24/2024		J(3)		11,433,448	A	$0.545	20,038,903	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were returned to treasury and cancelled

2. The total holdings of BIXT by NDPA Pharma, an affiliate whose beneficial ownership includes David Platt, Ola Soderquist and Mike Sheikh were consolidated under indirect ownership in David Platt's filing

3. The shares were issued as payment for the sale of NDPD to Bioxytran

	David Platt	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Bioxytran (BIXT) report for David Platt?

The Form 4/A shows that David Platt, Bioxytran’s CEO, director, and 10% owner, reported changes in his indirect holdings of preferred shares held through NDPD Pharma on 10/24/2024.

How many Bioxytran preferred shares were cancelled in the David Platt filing?

The filing reports that 14,085,410 preferred shares of Bioxytran were returned to treasury and cancelled from holdings through NDPD Pharma.

How many Bioxytran preferred shares did David Platt indirectly acquire?

On 10/24/2024, 11,433,448 preferred shares of Bioxytran were issued as payment for the sale of NDPD to Bioxytran, increasing David Platt’s indirect beneficial ownership.

What is David Platt’s indirect beneficial ownership in Bioxytran after these transactions?

Following the reported transactions, 20,038,903 preferred shares of Bioxytran are beneficially owned indirectly by David Platt through NDPD Pharma.

Why were NDPD Pharma’s Bioxytran holdings consolidated under David Platt?

The explanation states that NDPD Pharma’s BIXT holdings, whose beneficial ownership includes David Platt, Ola Soderquist, and Mike Sheikh, were consolidated under indirect ownership in David Platt’s filing.

What was the consideration for the new Bioxytran preferred shares issued to David Platt’s affiliate?

The filing notes that the 11,433,448 preferred shares were issued as payment for the sale of NDPD to Bioxytran.